Mar 7, 2008 by Brian LawlerA Little Too Much Drug VariabilityAnother drugmaker has to recall batches of its compound.
Mar 6, 2008 by Brian Lawler2008 Should Make or Break MannKindMannKind updates investors on what to expect this year.
Mar 5, 2008 by Brian LawlerFlamel in a NutshellAfter a choppy year, the drugmaker says there are plenty of new possibilities in its pipeline.
Mar 5, 2008 by Brian LawlerPDL Taken Off the BlockUnable to find a buyer, the pharmaceutical announces another restructuring.
Mar 3, 2008 by Brian LawlerActivist Investor Attack at EndoAn Endo shareholder releases an open letter in an SEC filing.
Mar 3, 2008 by Brian LawlerThe FDA's Call for CashIf more money would speed approvals, drug companies should be happy.
Mar 3, 2008 by Brian LawlerGood News Is Balm for GileadNIH backs Gilead's top drugs with positive results of a comparison study.
Mar 3, 2008 by Brian LawlerThree Health-Care Stocks to WatchTurn your attention to these health-care companies.
Mar 3, 2008 by Brian LawlerWatching Big Pharmas' InvestmentsInvestors need to take a look at large drugmakers' balance sheets.
Feb 29, 2008 by Brian LawlerRegeneron's Orphan Charms the FDAThe drug to treat a rare disease gets the OK.
Feb 29, 2008 by Brian LawlerNeurogesX Gets a Painful Kick in the PantsNeurogesX's lead drug fails in clinical testing.
Feb 29, 2008 by Brian LawlerAmgen Playing HardballNew developments in the Amgen and Roche patent fight.
Feb 29, 2008 by Brian LawlerFDA Floors Eli LillyIt rejects Zyprexa LAI, which would have made it easier to treat schizophrenics.
Feb 28, 2008 by Brian LawlerFDA's Mixed Signals for TheravanceThe FDA gives Theravance double messages about a lead drug.
Feb 28, 2008 by Brian LawlerFeeling Good About CV TherapeuticsFDA decisions could determine whether it builds on recent success with its lead drug.
Feb 28, 2008 by Brian LawlerMedicare, Health Care, and MegabucksA new government report forecasts big growth in health-care spending.
Feb 28, 2008 by Brian LawlerAlpharma on a MissionIts earnings were down partly because it's getting ready to put a pain patch on the market.
